Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Merck
Mallinckrodt
Boehringer Ingelheim
QuintilesIMS
Baxter
Medtronic
Deloitte
Chubb

Generated: November 12, 2018

DrugPatentWatch Database Preview

Sun Pharma Global Company Profile

« Back to Dashboard

What is the competitive landscape for SUN PHARMA GLOBAL, and when can generic versions of SUN PHARMA GLOBAL drugs launch?

SUN PHARMA GLOBAL has eighty approved drugs.

There are eight US patents protecting SUN PHARMA GLOBAL drugs. There are eight tentative approvals on SUN PHARMA GLOBAL drugs.

Summary for Sun Pharma Global
US Patents:8
Tradenames:70
Ingredients:69
NDAs:80
Patent Litigation for Sun Pharma Global: See patent lawsuits for Sun Pharma Global

Drugs and US Patents for Sun Pharma Global

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global DILTIAZEM HYDROCHLORIDE diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 090421-003 Nov 15, 2010 AB4 RX No No ➤ Sign Up ➤ Sign Up
Sun Pharma Global GEMCITABINE HYDROCHLORIDE gemcitabine hydrochloride INJECTABLE;INJECTION 078433-001 Jul 25, 2011 AP RX No No ➤ Sign Up ➤ Sign Up
Sun Pharma Global CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY cetirizine hydrochloride TABLET, CHEWABLE;ORAL 090142-001 Aug 30, 2011 OTC No No ➤ Sign Up ➤ Sign Up
Sun Pharma Global ENTACAPONE entacapone TABLET;ORAL 090690-001 Jul 16, 2012 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SUN PHARMA GLOBAL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 125 mg ➤ Subscribe 2018-07-23

Supplementary Protection Certificates for Sun Pharma Global Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00C/032 Belgium ➤ Sign Up PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
2008013 Lithuania ➤ Sign Up PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
0564409/01 Switzerland ➤ Sign Up PRODUCT NAME: IMATINIB; REGISTRATION NO/DATE: IKS 55807 20010621
C0009 Belgium ➤ Sign Up PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Colorcon
US Army
Fuji
McKinsey
UBS
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.